From Research to Practice: The Role of Mirabegron in Managing Overactive Bladder (OAB).

Authors

  • Arijit Ghosh Department of Physiology, Netaji Nagar College for Women, Kolkata

Abstract

Overactive bladder (OAB) is a prevalent condition affecting millions of people worldwide which is characterized by urinary urgency, frequency, and nocturia, leads to compromise in patients quality of life. Traditional treatments consisting of antimuscarinic agents have limitations due to the side effects and reduced long-term effectiveness which creates a demand for alternative therapies. Since the release of mirabegron in 2012, the treatment approach for overactive bladder (OAB) has shifted from antimuscarinics to β3-adrenergic receptor agonists. This review examines the effectiveness of mirabegron in OAB patients and its integration into clinical practice. New advances in disease management depend on the accumulation and incorporation of trial and clinical use data into guidelines for clarity. This is evident in the management of overactive bladder syndrome (OAB) with mirabegron. The landscape has changed, providing new options for healthcare professionals. We will discuss the latest data on mirabegron use, efficacy, safety, and cost-effectiveness and its potential use in combination therapies. In addition to its position in OAB management pathways, we will also explore future use of this β3-agonist.

Keywords:

Overactive bladder (OAB), Mirabegron, antimuscarinic agents

DOI

https://doi.org/10.25004/

References

Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11(3):117-25. doi: 10.1159/000447205.

Lukacz ES, Emily M, Whitcomb M, Lawrence JM, Nager CW, Karl M, et al.

Urinary frequency in community-dwelling women: what is normal ? Am J Obstet Gynecol. 2009;200:552.e1-552.e7. doi: 10.1016/j.ajog.2008.11.006.

Cheng Y, Chen T, Zheng G, Song Z, Zhang G, Rao X, et al. Prevalence and

trends in overactive bladder among men in the United States, 2005–2020. Scientific Report. 2024;14, 16284. doi: 10.1038/s41598-024-66758-8.

Rashid S, Babur MN, Khan RR, Khalid MU, Mansha H, Riaz S. Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan. Pak J Med Sci. 2021; 37(4):1185-89. https://doi.org/10.12669/pjms.37.4.4262.

Kim SY, Bang W, Choi HG. Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. PLoS One. 2017; 12(9): e0185592. doi: 10.1371/journal.pone.0185592.

Qudah S, Abufaraj M, Farah R, Almazeedi A, Ababneh A, Alnabulsi M, et al. The prevalence of overactive bladder and its impact on the quality of life: A cross-sectional study. Arab J Urol. 2023;22(1):39-47. doi: 10.1080/2090598X.2023.2221403.

Lee KS, Choo MS, Seo JT, Kim HG, Ng K, Lee KJ, et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015;26:13:89. doi: 10.1186/s12955-015-0274-9.

Choi H, Bae JH. Overview of the epidemiology of lower urinary tract dysfunction in South Korea. Int Neurourol J 2016;20(2):91-100. doi: 10.5213/inj.1630502.251.

Funada S, Luo Y, Uozumi R, Watanabe N, Goto T, Negoro H, et al. Multicomponent intervention for overactive bladder in women. JAMA Netw Open. 2024;7(3):e241784. doi: 10.1001/jamanetworkopen.2024.1784.

Salvatore S, Espuna-Pons M, Tubaro A. Urinary urgency: A Symptom in need of a cure. Res Rep Urol. 2019;11:327-331. doi: 10.2147/RRU.S216757.

Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;6:3:17042. doi: 10.1038/nrdp.2017.42.

Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis. European Urology. 2012;62: 877–90. doi: 10.1016/J.EURURO.2012.07.004.

Tomaszewski J. Postmenopausal overactive bladder. Prz Menopauzalny. 2014;13(6):313-29. doi: 10.5114/pm.2014.47984.

Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71-6. doi: 10.2147/RRU.S102441.

Shawahna R, Hijaz H, Jallad K, Abushamma M, Sawafta M. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study. BMC Urol. 2021; 21(1):142. doi: 10.1186/s12894-021-00909-1.

Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816. doi: 10.1155/2011/820816.

Welk B, McClure. The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia. Eur Urol Open Sci. 2022;46:22-29. doi: 10.1016/j.euros.2022.10.008.

Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Ueno K, et al. Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial. BMC Urology. 2020;20:129. doi: 10.1186/s12894-020-00697-0.

Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 2012; 125(9):1157-70. doi: 10.1161/CIRCULATIONAHA.111.039453.

Araklitis G, Baines G, Silva AS, Robinson D, Cardozo L. Recent advances in managing overactive bladder. F1000Res 2020;9:F1000 Faculty Rev-1125.

doi: 10.12688/f1000research.26607.1.

Kuo HC. Individualizing medical treatment of overactive bladder. Tzu Chi Med J. 2018;30(4):195–199. doi: 10.4103/tcmj.tcmj_83_18.

Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189-99. PMID: 18360559.

Ochoa DC, Bouchard B, Abrams P. A historical perspective on anticholinergics in overactive bladder (OAB) treatment: Foundations, current practices, and future prospects. Continence. 2024;12:101707. https://doi.org/10.1016/j.cont.2024.101707.

Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther 2018; 189:130-148. doi: 10.1016/j.pharmthera.2018.04.010.

Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Groat WC, Fryer AD, et al.

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565-78. doi: 10.1038/sj.bjp.0706780.

Kuei CH, Peng CH, Liao CH. Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist. Urological Science. 2015;26(1):17-23. https://doi.org/10.1016/j.urols.2014.12.007.

Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204-216. doi: 10.1177/2042098616659412.

Wani M, Sheikh MI, Bhat T, Bhat Z, Bhat A. Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review. Curr Urol 2021;15(3):153-160. doi: 10.1097/CU9.0000000000000037.

O’Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the Management of Overactive Bladder Syndrome. Int J Womens Health. 2022;14:1337-50. doi: 10.2147/IJWH.S372597.

Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). European Urology Focus. 2020;6:729-37. doi: 10.1016/j.euf.2019.10.019.

Frankel J, Saskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Ther Clin Risk Manag. 2022;18:171-182. doi: 10.2147/TCRM.S310371.

Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd Jr PN. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison. Adv Ther. 2021;38(11):5452-5464. doi: 10.1007/s12325-021-01902-8.

Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, Nazir J, Chapple C. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018; 4(3):324-33. doi: 10.1016/j.eururo.2018.03.020.

Huang CK, Lin C, Lin AT. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep. 2020; 10(1):11355. doi: 10.1038/s41598-020-68170-4.

Kim TH, Lee K. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57(2):84-93. doi: 10.4111/icu.2016.57.2.84.

Schonburg S, Murgas S, Fornara P, Michel MC. Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. Neurourol Urodyn. 2022;41(6):1399-1405. doi: 10.1002/nau.24960.

Smits E, Andreotti F, Houben E, Crijns H, Haas S, Spentzouris G, et al. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs Real World Outcomes. 2022;9(2):199-209. doi: 10.1007/s40801-021-00289-w.

Dehvari N, Silva Junior ED, Bengtsson T, Hutchinson DS. Mirabegron: potential off target effects and uses beyond the bladder. Br J Pharmacol. 2018;175(21):4072-4082. doi: 10.1111/bph.14121.

Yamada S, Niiya R, Ito Y, Kato Y, Onoue S. Comparative characterization of b-adrenoceptors in the bladder, heart, and lungs of rats: Alterations in spontaneously hypertensive rats. Journal of Pharmacological Sciences. 2022;148:51-5. doi: 10.1016/j.jphs.2021.10.003.

Igawa Y, Aizawa N, Michel MC. β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions ? Br J Pharmacol. 2019;176(14):2525-38. doi: 10.1111/bph.14658.

Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017;11:463-7. doi: 10.2147/DDDT.S101630.

Bamfo NO, Hosey-Cojocari C, Benet LZ, Remsberg CM. Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans. Pharm Res. 2021;38(7):1139-56. doi: 10.1007/s11095-021-03076-y.

Ritchey ME, Wang J, Young JC, Chandra R, Carrera A, Goti N, et al. CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis. Drugs Real World Outcomes. 2023;10(1):119-29. doi: 10.1007/s40801-022-00339-x.

Chen L, Zhou L, Huang J, Wang Y, Yang G, Tan Z, Wang Y, Zhou G, Liao J, Ouyang D. Single- and Multiple-Dose trials to determine the pharmacokinetics, safety, tolerability, and sex effect of oral ginsenoside compound K in healthy Chinese volunteers. Front Pharmacol. 2018;8:965. doi: 10.3389/fphar.2017.00965.

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189(4):1388-95. doi: 10.1016/j.juro.2012.10.017.

Orri M, Lipset CH, Jacobs BP, Costello AJ, Cummings SR. Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemp Clin Trials. 2014;38(2):190-7. doi: 10.1016/j.cct.2014.04.009.

Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a β3 –adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022;29(1):7-15. doi: 10.1111/iju.14700.

White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;12(11):768-778.e1. doi: 10.1016/j.jash.2018.08.001.

Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397(10285):1625–36. doi: 10.1016/S0140-6736(21)00590-0.

Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.

Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol 2024;212(1):11-20. doi: 10.1097/JU.0000000000003985.

Turell W, Howson A, MacDiarmid SA, Rosenberg MT. Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management. Int J Clin Pract. 2020;74(11):e13604. doi: 10.1111/ijcp.13604.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019;36(8):1906-21. doi: 10.1007/s12325-019-00994-7.

Yi W, Yang Y, Yang J. Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(41):e27469. doi: 10.1097/MD.0000000000027469.

Lin CS, Khan H, Chang R, Liao W, Chen Y, Siao S, et al. A study on the impact of poor medication adherence on health status and medical expense for diabetes mellitus patients in Taiwan: A longitudinal panel data analysis. Medicine (Baltimore). 2020;99(26):e20800. doi: 10.1097/MD.0000000000020800.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425-34. doi: 10.1111/luts.12382.

Andersson KE. On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder. Int Neurourol J. 2017;21(1):6-11. doi: 10.5213/inj.1734850.425.

Kuo Y, Kuo H. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients. Tzu Chi Medical Journal. 2023;35(1): 62-8. doi: 10.4103/tcmj.tcmj_209_21.

Parise H, Espinosa R, Dea K, Anaya P, Montoya G, Ng DB. Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia. Pharmacoecon Open. 2020;4(1):79-90. doi: 10.1007/s41669-019-0149-9.

Published

30-01-2025
Statistics
Abstract Display: 11
Dimension Badge

How to Cite

“From Research to Practice: The Role of Mirabegron in Managing Overactive Bladder (OAB)”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 17, no. 1, Jan. 2025, https://doi.org/10.25004/.

Issue

Section

Review Article

How to Cite

“From Research to Practice: The Role of Mirabegron in Managing Overactive Bladder (OAB)”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 17, no. 1, Jan. 2025, https://doi.org/10.25004/.

Similar Articles

1-10 of 106

You may also start an advanced similarity search for this article.